Cadence Pharmaceuticals announced on November 14 that the US District Court for the District of Delaware ruled in its favour in its patent infringement suit against Exela Pharma Sciences LLC.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Cadence, Ofirmev, patent infringement, Exela
